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With greater technological advancements and understanding of pathophysiology, “personalized medicine” has
become a more realistic goal. In the field of cancer, personalized medicine is the ultimate objective, as each cancer is
unique and each tumor is heterogeneous. For many decades, researchers have relied upon studying the
histopathology of tumors in the hope that it would provide clues to understanding the pathophysiology of cancer.
Current preclinical research relies heavily upon two-dimensional culture models. However, these models have had
limited success in recreating the complex interactions between cancer cells and the stroma environment in vivo. Thus,
there is increasing impetus to shift to three-dimensional models, which more accurately reflect this phenomenon.
With amore accurate in vitro tumormodel, drug sensitivity can be tested to determine the best treatment option based
on the tumor characteristics. Many methods have been developed to create tumor models or “tumoroids,” each with
its advantages and limitations. One significant problem faced is the replication of angiogenesis that is characteristic of
tumors in vivo. Nonetheless, if three-dimensional models could be standardized and implemented as a preclinical
research tool for therapeutic testing,wewould be taking a step towardsmaking personalized cancermedicine a reality.
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Cancer was responsible for 1.23 million deaths within the European
Union in 2008 [1]. In the United Kingdom, the incidence of all types
of cancer was over 520 cases per 100,000 people, with the four most
common cancers being breast, lung, colorectal, and prostate [2].
The health care cost of cancer within the European Union has been
estimated at just under £44 billion. This is only around 40% of the
total cost of cancer to society, which takes into account productivity
loss among other factors [1]. As a consequence, a vast sum of money is
invested into producing cancer treatments, which currently only
produce around a 45% 10-year survival rate [3]. As such, the
production of highly effective cancer treatment is a vital area of
research. In order to test drug efficacy and the specific resistance of
cancers to certain drugs, there must be new methods of producing
pertinent in vitro representations of solid tumors very similar to those
that occur in vivo. (See Table 1).Two-dimensional (2D) monolayers remain the standard for cancer
drug discovery, even though 2D monolayers are unable to replicate
the complicated environment and mechanisms of a solid tumor and
its growth [4,5]. The production of three-dimensional (3D) in vitro
Table 1. Summary of Advantages and Disadvantages of Various Techniques Used to Engineer 3D Tumor Models
Advantages Disadvantages
Cellular spheroid
a. Rotary cell culture system
b. Hanging drop plate
c. Hanging drop array
d. Microarray
e. Collagen-implanted spheroids
• Produces a large number of spheroids
• Consistent sizes
• Does not require external scaffold
• Easily applied to high-throughput screens
• Spherical shape enables modeling of tumor growth and invasive processes [13]
• Complexity needs to be improved to better mimic in vivo tumors
• TM: not all cell types and ECM components represented in models [12–16]
Organotypic explant culture • Preserves tissue cytoarchitecture • Heterogeneity of explanted tissue
• Imaging challenging due to low transparency [9,12]
Polarised epithelial cell culture • Relatively high throughput • Expensive [12,17]
Gyratory and spinner flasks • Cheap
• Easy to use
• Produce a large number of spheroids
• Shear stress affects spheroid architecture [13]
Mircocarrier beads • Cheap
• Suitable for anchorage-dependent cell lines
• Require use of gyratory/spinner flasks; same problem of shear stress [12]
Artificial skin • Able to model complex epithelial structures using support structures such as membrane inserts • Expensive [12]
Artificial Cancer Mass • Biomimetic
• Use of plastic compression technique increases cell and matrix density
• Expensive
• Difficult to culture sensitive cell lines [18,19]
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Figure 1— is now established as a much more accurate representation
of in vivo conditions when compared to other in vitromodels, such as
the production of 2D monolayers [6]. This advancement is vital given
the vast heterogeneity within tumors. A great number of factors must
be taken into account when examining a tumor; growth, adhesion,
metastasis, invasion, response to growth factors, angiogenesis, and
tissue remodeling are all important considerations when producing a
precise model. Cancer cells have complex interactions with
surrounding cells and the extracellular matrix (ECM), and 3D tissue
cultures more accurately reflect this not only on a biochemical and
mechanical level but also on the level of gene and protein
expression [7]. (See Figures 2 and 3).
There are two clear aims for improving cancer treatment: to
improve the testing of new drugs and to increase the efficacy of drugs
that are currently available. More complex tumor models more closely
mimics the response seen clinically, facilitating these aims by allowing
more accurate examination of drug sensitivity and resistance [8].
From a Single Cell to a Sphere
WhatTechniquesCanBeUsed toEngineerThese InVitroTumoroids?
Conventionally, tissues are harvested in vivo and subsequently
explanted and cultured in vitro [9]. Tumoroids created by xenografting
retain their architecture in culture and have proven to be an effective
method for many tissues, including the brain and embryonic glands
[10,11]. However, thesemodels are time consuming and expensive, and
it is difficult to image these thick, light-scattering tissues without
incurring photodamage [12]. Thus, culturing in vitro tumoroids is an
alternative ex vivo approach that involves using isolated cells from cell
lines, dissociated tissues, or stem cells [9].
3D tumoroids that accurately mimic tumor pathophysiology have
been successfully engineered through numerous methods. Currently,
there are seven main methods used: cellular spheroids [12–16],
organotypic explant culture [9,12], polarized epithelial cell culture
[12,17], gyratory [13] and spinner flasks, artificial skin [12],
microcarrier beads [12], and artificial cell masses [18,19].
3D models are most commonly fabricated using cellular spheroid
production techniques. This takes advantage of the natural tendency
for cells to form aggregates, reestablishing cellular connections.The spheroid microenvironment enables them to differentiate,
forming a tissue-like phenotype that is similar to an in vivo tumor
[12]. Cancer models created by this technique can be formed by five
main methods: rotary cell culture system [20], microarray [16],
hanging drop plate technique [21,22], hanging drop array [14], or
collagen-implanted spheroids [15]. These systems are capable of
producing large numbers of consistently sized spheroids. Additionally,
they can be easily applied to high-throughput screens using the 384
hanging drop array [14], and the spherical shape allows tumor growth
and invasive processes to be modeled [12]. Apart from collagen-
implanted spheroids, the cellular spheroids technique negates the need
for an external scaffold [12]. Collagen-implanted spheroids are
advantageous in that they contain a biodegradable scaffold.
There needs, however, to be a common consensus regarding the
definition of a spheroid as it has been misused to describe loose
aggregates that detach easily, lack cell–cell and/or cell–matrix
interactions, or do not have a spherical geometry [16]. The complexity
of thesemodels can however be further enhanced, and there is a need for
the tumor microenvironment (TM) to be better represented.
Although many methods have been developed, each method has its
own set of advantages and limitations. In addition, different methods
may be more suitable for studying different mechanisms. A balance
needs to be struck between achievability, complexity of the tumor,
suitability, and cost before deciding which method should be
employed to investigate a particular mechanism.
Varying Factors to Engineer the Ideal Tumor
Tumoroid characteristics can be tailored to study various mecha-
nisms. Factors that influence these characteristics include tumor size,
which influences oxygenation and the number of cell lines used.
3D models are inherently avascular tumors and rely solely on
diffusion for nutrient and oxygen transport. Hence, by altering the
size of tumoroids, various stages leading up to the formation of
necrotic regions can be studied. Smaller tumoroids (400 to 600 μm)
would contain viable cells at the rim and core region, while larger
tumoroids would instead possess a characteristic necrotic core [6].
Some studies require tissues to be thin (~0.3 mm) to enable the
interior of the tissue to receive adequate oxygenation and nutrition
[9]. Other studies focus on mimicking the distinctive nutrient
insufficiency within the tumor’s interior, which induces the
Figure 1. Summary of 3D tumor models. There are seven main methods: 1) Cancer models created by cellular spheroid technique can be
formed by five main methods: rotary cell culture system [20], microarray [16], hanging drop plate technique [21,22], hanging drop array
[14], or collagen-implanted spheroids [15]. 2) Organotypic explant culture involves dissecting organs into slices, which are subsequently
cultured on a semiporous membrane or embedded in a collagen matrix, and grown in an air–liquid growth medium interface [12].
3) Polarized epithelial cell culture is an approach in which cells are grown on a porous membrane, forming polarized monolayers [12].
4) Gyratory and spinner flasks are used to culture cells in suspension; the fluid movement aids transport of both nutrients and waste,
facilitating growth of the spheroid [13]. 5) Microcarrier beads made from various materials, including dextran, gelatine,
glycosaminoglycans, and other porous polymers, can be used to create these tumoroids by acting as a support structure for culture
of cell lines that are anchorage dependent [12]. 6) Artificial skin can also be used as a 3D culture model. It is made up of three main layers:
the fibroblast and a biodegradable fibre mesh layer, which together form the dermis, and keratinocytes, which form the epidermis [12].
Fibroblasts are first cultured in vitro and seeded onto the fiber mesh layer. Keratinocytes are then added to the dermal tissue to form the
epidermis [12]. 7) Artificial cancer masses are created by seeding cancer cells onto a collagen hydrogel. Plastic compression is then
applied to enhance cell and matrix density [18,19].
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(nutrient insufficiency and necrosis) in a controlled setting is crucial
in understanding tumor–host interactions. For instance, growing 3D
models could provide better insight into mechanisms involved in
angiogenesis, chemotherapy drug resistance [23], cell adhesion, and
migration [12]. For instance, Hicks et al. demonstrated that the use of
a 3D culture in a mouse model could predict therapeutic activity of
anticancer drug tirapazamine [23]. Additionally, the oxygen and
nutrient gradients would enable intratumor heterogeneity to be
captured within these 3D models. Lawrenson et al. have developed a
3D in vitro model to study the genetic and clinical heterogeneity in
ovarian epithelial cancer [24].
Aside from varying tumor size, 3D models can be bioengineered to
be either simple cancer spheroids or tumoroids comprising multiplecell lines. Multicellular tumoroids are cultured from established
cancer cell lines or disaggregated samples from human tumors [18].
Recently, 3D models have been able to successfully mimic the early
steps of metastasis such as epithelial mesenchymal transition [25].
Studies by Fischbach et al. have shown that 3D cultured human
oral epithelium cells (OSCC-3) can transition into a fibroblastic
morphology and also have invasive potential [26]. More excitingly,
cancer stem cells (CSCs), which are cells found within solid tumors
that play a role in initiation, recurrence, and metastasis, have also been
used to create 3D models. Chen et al. demonstrated the use of a
nonadhesive culture system using CSCs derived from OSCC, which
showed higher levels of therapeutic resistance [27]. This nonadhesive
system allows spheres to detach and subsequently form small clusters,
triggering anoikis due to its inability to attach [27]. Models like this
Figure 2. Figure illustrates some of the fundamental milestones which must be met before in vitro models can accurately recreate the
tumor microenvironment.
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mechanisms behind cancer cell proliferation without proper anchorage,
and avoid anoikis.
The implications of such advancement could mean not only the
cheaper production of more efficacious drugs and an improvement in
the successful treatment of cancers but also a transition towards a system
of stratified treatment. Theoretically, a tumor could be biopsied and itsFigure 3. Illustration of the complex concentric architecture typically
metabolites typically establish three distinct zones in the tumoroid:
apoptotic/necrotic core. Proximity to vasculature ensures that there i
efficient removal of waste products, permitting high levels of cell pro
a buildup of toxic metabolites such as CO2 and lactate, and subsequcells then cultured using an appropriate method, producing a 3D
tumoroid. The sensitivity and resistance could then be tested to
determine and subsequently produce a treatment that is tailored to the
biopsied tumor. Although this would mean more effective treatment
against specific tumors, it is unlikely to be implemented within the
near future. Nevertheless, advances in techniques have enabled rapid
(b24 hours), high-throughput generation of tumoroids [6].observed in tumoroids. Concentration gradients of nutrients and
an outer proliferative zone, a middle quiescent zone, and an inner
s an abundance of oxygen and glucose peripherally, along with the
liferation. Centrally, low levels oxygen lead to anaerobic respiration,
ent cell apoptosis.
Translational Oncology Vol. 7, No. 6, 2014 Personalized In Vitro Cancer Modeling Bartlett et al. 661Important Considerations in Modeling the
Tumor Microenvironment
In order for 3D in vitro models to be of use in stratified medicine,
both in unlocking the specific mechanisms underlying invasion and
metastasis and in allowing the assessment of drug efficacy, they must
accurately recreate the complex TM. Although the TM is poorly
understood, there are some fundamental aspects which are integral to
the creation of any useful in vitro tumor model.
Concentric Architecture
Tumoroids in vivo display some degree of concentric architecture.
Typically, tumors display three relatively distinct zones [8]: an outer
mitotically active proliferative zone, a middle quiescent zone, and an
inner apoptotic/necrotic zone. These somewhat distinct concentric
layers are established due to the relative distance of cancer cells from
the surrounding vasculature. The outermost cells, being closest to the
vasculature, benefit from rapid removal of toxic metabolites and ready
access to nutrients and oxygen [16]. For instance, Nyga et al.
demonstrated the presence of concentricity through the measurement
of the oxygen gradient through a tumoroid using a real-time oxygen
probe [18]. In the presence of oncogenic mutations and the vast
supply of nutrients, they are free to rapidly proliferate with low
concurrent levels of apoptosis. In contrast, the innermost cells of a
tumor undergo apoptosis and necrosis due to chronic pathological
hypoxia and the accumulation of toxic metabolites.
An accurate 3D in vitro tumor model must ensure that this
architecture is established and maintained since varying pH levels
throughout the tumoroid greatly affect drug distribution. Raised
levels of lactate in the necrotic core decreases pH centrally, and hence
the actions of weakly basic drugs, such as chlorambucil and
mitomycin C, are potentiated. In contrast, weakly acidic drugs such
as mitoxantrone and anthracyclin will often show good efficacy in
monolayers models, but their poor distribution to the acidic core
in 3D means that their overall action is often seen to be attenuated
in vivo [8].Detachment & Invasion of Surrounding Tissue
Tumors in vivo will typically undergo cell–cell and cell–matrix
detachment and extravasation and form metastases. This process is
essential in any invasive tumor, and cancer models should replicate
this [28].
A recent study by Nyga et al. has successfully demonstrated the
successful detachment of HT29 colorectal cancer cells seeded in a
type I collagen matrix populated with fibroblasts and epithelial cells
[19]. The mechanisms behind this detachment were not elucidated in
the study; however, other literature suggests that integrin class-
switching may be at least partially responsible for cell detachment.
Hanahan et al. propose that integrin isotypes α3β1 and αVβ3 may be
particularly useful in promoting the detachment of cells from their
native ECM in favor of ECM that is highly protease susceptible [29],
hence encouraging rapid metastasis. Specifically, αVβ3 may play an
important role preventing anoikis when metastatic cells encounter
ex situ ECM due to its relatively unspecific ligand binding [30].
Future research efforts should concentrate on analyzing the metastasis
of tumoroids from a native ECM TM to a protease-susceptible,
prometastatic form; 3D in vitro models should explicitly assess the
mechanism by which metastatic cells integrin class-switch to cause
extravasation to lymphatic tissue, although involvement of the PI-3 K
pathway is strongly suspected [31].Cell Microenvironment
ECM stiffness has been found to regulate gene and protein expression
in cells, affecting cell morphology and behavior via integrin mediated
cell–cell signaling, which has an established role in cancer progression
[25]. Dynamic forces such as flow, stretch, and diffusion are important
components of the cell microenvironment [32]. For example, it is
known that shear forces exerted by fluid flow affect angiogenesis and the
laying down of endothelium, which stabilizes the vasculature [33]. As
such, there has been increasing interest in the effects of a dynamic and
mechanical microenvironment on cancer cells and its surrounding
stroma [32]. In 3D models, mechanical stresses can be altered through
the selection and/or modification of the scaffolds, allowing further
research into this phenomenon [26,33]. ECM stiffness modeling is
important in allowing us to understand andmimic themalignancy of the
tumor and thus further aids drug development.
Immune Interface
The concept of a reactive stroma is that immune responses
synergize with other processes to cause a characteristic stroma that
promotes cancer progression [9,25]. For example, an increased
efficiency in the induction of endothelial cell tubule formation was
seen in vitro with the co-culture of cancer cells with macrophages.
This was believed to be caused by the release of inflammatory cytokines
by the macrophages [34].
Furthermore, there is evidence to suggest that the cells of the hypoxic
core may be protected from routine immune surveillance in vivo due to
high local concentrations of lactate substantially downregulating the
effects of cytotoxic T-lymphocytes [35]. Therefore until more accurate
tumor-immune interfaces are created, the complex regulatory feedback
systems will remain unaccounted for, limiting the extent to which the
models can mimic the in vivo scenario.
Co-Culture and Its Significance on the TM
Co-culture of multiple cell types is essential in accurately creating
the TM. Stromal cells not only influence tumor cell behavior through
paracrine signaling but may also change cell behavior by altering the
mechanical properties of the support scaffold. One of the major types
of stromal cells is carcinoma-associated fibroblasts. Carcinoma-
associated fibroblasts secrete cytokines, growth factors, and also
matrix metalloproteases (MMPs) to remodel the ECM [36]. Pinilla et al.
demonstrated that co-culture of breast cancer cells with human adipose-
derived stem cells can cause upregulation ofMMP-9 due to the presence
chemokine ligand 5 [37]. This is significant because upregulation of
MMP-9 not only is key to the process of desmoplasia but also may act as
a key angiogenic “switch” [38].
Stromal cells regulate interstitial fluid volume and therefore interstitial
fluid pressure. This is particularly pertinent in tumoroid modeling, as
increased interstitial pressure has been associated with greater levels of drug
resistance and cell survival [39–41]. Thus, models that do not incorporate
stromal cells may be prone to giving inaccurate drug efficacy results.
It is established that co-culturing, which refers to the incorporation of
multiple cell types, canmore accurately replicate intratumor heterogeneity
[29].However,more research is needed in both stromal and immune cells
before in vitro models successfully replicate the in vivo TM.How Do 3D Models Improve
Pharmaceutical Testing?
Cancer is not a single disease, and it does not remain static in a given
patient. As treatment prognosis varies depending on location and
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treatment. At present, empirical therapy, which yields poor responses,
is still utilized. In non–small cell lung carcinoma, third-generation
drugs only achieve a 40% response rate [42]. With the maturity of 3D
tumor modeling techniques, tumoroids can be used to replicate both
primary tumors and metastases for chemosensitivity tests to
determine the best course of treatment for the individual patient
and hopefully increase response rates.
Evidence for the Use of 3D Models
Previous studies have used collagen gel droplet embedded culture
drug sensitivity testing (CD-DST) as a simplistic 3D model to
determine chemosensitivity in patients. CD-DST is a technique
where a suspension of tumor cells is added to a type I collagen
solution and the mixture is allowed to gel [42,43]. In one study,
patients treated with in vitro sensitive drugs showed a response rate of
85.7%, whereas patients treated with in vitro nonsensitive drugs only
showed a response rate of 41.7%. Evidence from other trials also
shows that drugs proven to be effective in vitro show better clinical
results in vivo [42–45]. Despite the lack of modification to the TM,
CD-DST still shows extremely promising results. It follows that the
increased system tunability afforded by the advances in tumor
modeling techniques would greatly enhance the translatability of
in vitro drug testing results to in vivo drug response.
Angiogenesis and Drug Response
Correa de Sampaio et al. recently developed a “Minitumor
Spheroid” 3D model incorporating endothelial cells, fibroblasts, and
cancer cells. When grown in a collagenous scaffold, capillary-like
sprouting was observed. A network of capillary structures with lumens
was observed after prolonged incubation. Similar to the in vivo
scenario, the vasculature responded to treatment with bevacizumab,
an anti-VEGF antibody, showing inhibition of angiogenesis [34].
Antiangiogenic agents thalidomide and endostatin demonstrated
successful inhibition of tumor angiogenesis in murine and crude
in vitro models. However, both drugs failed to show a significant
effect clinically. In concordance with clinical data, both drugs showed
no effect in the Minitumor. The success of the Minitumor in being an
accurate predictor of clinically efficacious drugs makes this a vast
improvement over past models, which mostly failed to incorporate
cancer cells, resulting in overly simplistic, unrepresentative models [34].
The study of this model may also shed some light on tumor-
associated vasculature, which is unlike vessels in healthy tissues. It is
often tortuous and leaky, resulting in poor perfusion and drug delivery
[46]. The interstitial fluid pressure of the tumor is often raised and is
believed to compress the vasculature, reducing perfusion [36,47].
Together, these make drug penetrance very difficult, and this is an
important determinant of efficacy [48]. Understanding themechanisms
of tumor-associated vasculature may then put us in a better position to
design drugs that can reach its target. Nevertheless, pharmaceutical
testing in 3D models is still in its infancy, as techniques for developing
these models have yet to be standardized and optimized.
Cancer Stem Cells
Recent studies have discovered a subset of tumor cells known as
CSCs. They possess characteristics similar to stem cells, including the
ability to self-renew. CSCs are believed to be resistant to chemotherapy,
persisting after treatment and potentially causing cancer recurrence
[27,49–51].In 2008, Li et al. found that there was a statistically significant
increase in the proportion of CSCs in patients postchemotherapy.
However, there was no significant change in CSC proportion in
patients who received lapatinib treatment followed by chemotherapy.
The CSC population, being less sensitive to chemotherapy, increased
in proportion without the adjuvant use of lapatinib. Lapatinib is an
epidermal growth factor receptor and HER2 inhibitor. It is believed
that epidermal growth factor receptor signaling is essential for CSC
self-renewal, and this explains why better control of CSCs was
achieved in the lapatinib group [52].
The work of Li et al. clearly demonstrates the insufficiency of
conventional chemotherapy. It is currently unclear exactly how self-
renewal of CSCs is regulated and their role in metastasis. More studies
must be done on CSCs to elucidate their characteristics. 3D cultures
allow that to happen and are also an avenue to test CSC-targeted
therapies [52].
Models grown from CSCs derived from primary tumors have shown
to mimic the in vivo behavior of the cancer cells more accurately than
those grown from established cell lines [50,53,54]. One challenge is
obtaining CSCs from a biopsy, as these cells are a subpopulation of the
tumor. Therefore, techniques to identify CSCs should be incorporated
into our proposed patient pathway. By identifying and obtaining CSCs,
we are then able to expand them in vitro and thus circumvent the
inaccuracies that stem from the use of established cell lines.
Challenges, Future Direction, and Conclusion
The patient pathway that we have proposed is an ideal that we strive
towards. However, there are some limitations. A biopsy of a tumor
only obtains a small proportion of the cells. The heterogeneity of the
tumor cell population means that the tumor model cultured may not
be entirely representative of the primary tumor. As previously
mentioned, another limitation is that CSCs may not be present in the
biopsy sample. Although not fool-proof, multiple biopsies can be
taken from different parts of the tumor to try to avoid this problem. It
may also be possible that, in the future, CSCs could be labeled,
facilitating their extraction during the biopsy.
For 3D modeling to be universally adopted, it must be cheap and
efficient, providing rapid results that can be translated to the clinical
situations. For this to happen, the process of culturing the tumor must
first be streamlined and standardized. Commercially available culture
kits would be the ideal solution. A high-throughput method of
analyzing the chemosensitivity of the tumor must then be devised and
implemented. This would allow for convenient, consistent culturing of
themodels and efficient analysis, culminating in rapid results that can be
translated into feasible treatment options for the patient.
At the same time, much more work needs to be carried out,
especially in the areas of simulating metastases, angiogenesis, and the
immune interface. In each of these areas, there have only been reports
of a few isolated successes. We are probably a distance away from fully
emulating the in vivo scenario in these areas. Nevertheless, current
tumor models have yielded very encouraging results, and with the vast
amount of research that is being carried out, personalized in vitro
modeling is no longer a fantasy.
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